Madrigal Pharmaceuticals Inc (MDGL)

[DMOST]

MDGL has now lost all the gains from the big bounce to $326...........Such be the way of the markets.

Meanwhile..........

Madrigal Pharmaceuticals Inc (MDGL) CEO Paul A Friedman Bought $496,000 of Shares
[GuruFocus.com]
GuruFocus.com
,GuruFocus.com•November 20, 2018

- By insider

CEO of Madrigal Pharmaceuticals Inc (MDGL) Paul A Friedman bought 4,000 shares of MDGL on 11/19/2018 at an average price of $124 a share. The total cost of this purchase was $496,000.

Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). Madrigal Pharmaceuticals Inc has a market cap of $1.85 billion; its shares were traded at around $120.50 . Madrigal Pharmaceuticals Inc had annual average EBITDA growth of 43.80% over the past five years.

Warning! GuruFocus has detected 5 Warning Signs with WBA. Click here to check it out.
MDGL 15-Year Financial Data
The intrinsic value of MDGL
Peter Lynch Chart of MDGL


CEO Recent Trades:

CEO Paul A Friedman bought 4,000 shares of MDGL stock on 11/19/2018 at the average price of $124. The price of the stock has decreased by 2.82% since.

Directors and Officers Recent Trades:

Director, 10% Owner Fred B Craves bought 2,000 shares of MDGL stock on 11/19/2018 at the average price of $124.69. The price of the stock has decreased by 3.36% since.

GO MDGL

"PEACE"